Esperion Therapeutics ESPR 深 沪
交易中 11-06 10:22:13 美东时间
2.57
-0.370
-12.59%
华盛通- 最 高2.78
- 今 开2.76
- 成交量 481.33万股
- 最 低 2.4235
- 昨 收 2.94
- 总市值 5.19亿
- 52周最高 3.94
- 市盈率 静 --
- 换手率 2.38%
- 52周最低 0.6925
- 委 比 7.86%
- 总股本 2.02亿
- 历史最高 120.96
- 量 比 10.33
- 振 幅 12.13%
- 历史最低 0.6925
- 每 手 1
- 风险率 0.70%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Snap Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
Shares of Snap Inc (NYSE:SNAP) rose sharply in pre-market trading after the com...
今天 19:32
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
今天 19:12
Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update
Esperion Therapeutics reported Q3 2025 total revenue of $87.3 million, up 69% Y/Y, driven by U.S. net product revenue growth of 31% to $40.7 million. The company reached a settlement agreement with Dr. Reddy's Laboratories to delay generic versions of NEXLETOL and NEXLIZET until 2040. Bempedoic acid received Level 1a recommendation in updated ESC/EAS guidelines. Partner Otsuka received regulatory approval for NEXLETOL in Japan, with favorable pri...
今天 11:00
Esperion Appoints New Chief Commercial Officer
An announcement from Esperion ( ($ESPR) ) is now available. On November 4, 2025...
11-04 22:19
Esperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2:00 p.m. ET.
Esperion Therapeutics will host a virtual KOL event to discuss statin intolerance challenges, patient outcomes, and the company's commitment to addressing this unmet need. The event, led by LeAnne Bloedon, will feature discussions with Dr. Fatima Rodriguez and Dr. Dharmesh Patel. Registration and a live webcast are available on Esperion's website.
10-28 12:00
Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025
Esperion Therapeutics (NASDAQ: ESPR) announced that two presentations on bempedoic acid, including a secondary analysis of the CLEAR Outcomes trial, will be presented at the AHA Scientific Sessions 2025 in New Orleans. The oral presentation will focus on LDL cholesterol and cardiovascular events, while the poster will examine venous thromboembolism effects. Both analyses highlight challenges with statin intolerance and emphasize the need for addi...
10-27 12:00
Esperion Nominates ESP-2001 as Preclinical Development Candidate for Treatment of Primary Sclerosing Cholangitis
Esperion announced the nomination of ESP-2001, a highly-specific allosteric ACLY inhibitor for the treatment of primary sclerosing cholangitis (PSC), targeting liver and bile duct injury, inflammation, and fibrosis. Preclinical data suggest ESP-2001 may significantly impact PSC progression, a disease with no approved treatments. The company plans to advance ESP-2001 through IND-enabling studies, aiming to file an IND with the FDA in 2025 and begi...
10-16 12:00
Dow Jumps Over 100 Points; US Crude Oil Inventories Increase
U.S. stocks traded higher midway through trading, with the Dow Jones index gain...
10-09 01:22
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Xenetic Biosciences (NASDAQ:XBIO) stock moved upwards by 137.1% to $10...
10-09 01:06
Esperion Therapeutics prices $75M public offering
Esperion Therapeutics (ESPR) is offering 30M shares of common stock at $2.50 per share in an underwritten public offering. The company has granted underwriters a 30-day option to purchase up to 4.5M a...
10-08 13:34
